The long-awaited FDA approval follows data that demonstrated about 70% wound closure by 6 months in dystrophic epidermolysis bullosa patients treated with B-VEC.
Patients with dystrophic epidermolysis bullosa face near-constant pain and discomfort. While there are several measures clinicians have to help them, a curative treatment remains elusive.
RARE Drug Development Symposium: Fostering Successful Connections Between Stakeholders to Accelerate Progress globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.